The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The dawn of a new era of targeted lipid-lowering therapies
Open accessAbstract
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis. Recent human genetic findings have substantiated a number of novel targets for lipid-lowering therapy including apolipoprotein C-III, angiopoietin-like protein 3 and 4, apolipoprotein V, and ATP citrate lyase. These discoveries coupled with advances in biotechnology development afford new avenues for management of LDL and other aspects of lipid risk. Beyond LDL, new treatments targeting triglyceride-rich lipoproteins and lipoprotein(a) have become available and have entered clinical development. Biological and RNA-directed agents have joined traditional small-molecule approaches, which themselves have undergone considerable refinement. Innovative targeting strategies have increased efficacy of some of these novel interventions and markedly improved their tolerability. Gene-editing approaches have appeared on the horizon of lipid management. This article reviews this progress offering insight into novel biological and therapeutic discoveries, and places them into a practical patient care perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“experts in both regulatory agencies in the USA and the European Union (EU)—from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—approved highly purified EPA, icosapent ethyl, for cardiovascular prevention in patients with dyslipidaemia.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Cited by
Sorted by citations
Items 101–170 of 170
Lowering of Lipoprotein(a) with Olpasiran
Amo-Tweneboah, C., & Kaur, G. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x428489260113103704 · Cited by 6
Acute and Subacute Oral Toxicity Evaluation of Baccaurea motleyana Fruit Extract in Wistar Rats
Hasan, M. M., Bhuyan, E. A., Ekram, M. E. H., Proma, N. M., & Hossain, M. K. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71744 · Cited by 3
Yang, J., Zhang, R., Han, B., Li, H. Z., Wang, J., Xiao, Y., Yu, X., Guan, S., Dai, C., Yan, H., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02244-4 · Cited by 3
Ou, G., Zhang, Y., Cai, H., Yao, K., Qiu, Z., Chen, Y., Yang, Y., Chen, Q., & Chen, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1446610 · Cited by 3
Zhao, L., Liu, J., Liu, Y., Huang, Z., Ye, X., Lange, J. L., Dhalwani, N. N., Yang, F., Zhang, Z., Chen, K., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03199-3 · Cited by 3
Kong, X., He, G., Quan, X., Tan, Z., Yan, F., & Chen, X.-H. (2024) · Medicine · doi:10.1097/md.0000000000037637 · Cited by 3
From Genetic Findings to new Intestinal Molecular Targets in Lipid Metabolism
May, C. L., Ducheix, S., Cariou, B., & Rimbert, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01264-w · Cited by 3
Imboden, M. T., Jones, K. G., Roth, S. E., Marsillo, R., Jones, L. K., Kalich, B. A., Sidelnikov, E., Gluckman, T. J., Rountree, J. A., Wilson, E., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.06.004 · Cited by 3
Formisano, E., Vignati, A., Bertolini, A., Barreto, V. S., Tafuro, M., Pasta, A., Sukkar, S. G., & Pisciotta, L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.018 · Cited by 4
A foam cell-targeted lipophagy restoration strategy stabilizes vulnerable atherosclerotic plaques
Li, H., Qin, Y., Zhang, J., Guo, X., Hu, X., Sun, D., Zhao, Y., Bernardini, S., Xu, D., Jiang, P., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.02.041 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Lalic, K. S., Rajkovic, N., Popović, L., Lukač, S. S., Rasulić, I., Petakov, A., Krstic, M., & Mitrović, M. (2024) · Galenika Medical Journal · doi:10.5937/galmed2409031l · Cited by 2
Baig, S., Mughal, S., Murad, Y., Virdee, M., & Jalal, Z. (2024) · Pharmacy · doi:10.3390/pharmacy12040104 · Cited by 1
Lipid management in patients newly referred to a vascular surgery outpatient clinic
Vergouwen, M., Bayrouti, A., Krzyzaniak, H., & Petrasek, P. F. (2025) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2025.100231 · Cited by 1
Peng, L., Zhou, G., Hu, J., Yao, Y., Huang, Q., Yu, A., & Wang, Y. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.164344 · Cited by 2
Toda, M., Iekushi, K., Takahashi, Y., & Kohsaka, S. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03321-5 · Cited by 1
Proteomic Biomarkers Are Linked to QTc Interval in Patients With Chronic Heart Failure
de Jong, M. B., Petersen, T. B., Kamar, S. A., Suthahar, N., van Boven, N., Akkerhuis, K. M., van der Spek, P. J., Katsikis, P. D., de Boer, R. A., Umans, V. A. W. M., et al. (2025) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70020 · Cited by 1
Moges, T. A., Dagnew, S. B., Anberbr, S. S., Bitew, B. E., Kiflu, M., Ferede, Y. A., Yiblet, T. G., & Zewdu, W. S. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251381590 · Cited by 1
Zhao, L., Lv, X., Chen, W., Li, X., Zhou, J., Ai, Q., & Tuo, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616096 · Cited by 1
Liu, Q., Cheng, Z., Wu, T., Ke, B., & Shen, W. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039855 · Cited by 1
Lu, H., Huang, Q., Xiong, Z., Wu, C., Ren, S., Wang, X., & Shi, J. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.172968 · Cited by 2
Hou, Y., Zhang, X., Sun, X., Qin, Q., Jia, M., Su, X., & Chen, Y. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.324122 · Cited by 1
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Level of Nurses Knowledge Regarding Heart Failure Education in Three Major Hospitals of Peshawar
Ghani, S., Ali, N., Ghani, N., & Khattak, I. (2023) · Journal of Health and Rehabilitation Research · doi:10.61919/jhrr.v3i2.142 · Cited by 1
Der Einsatz einer perkutanen Impella CP im Rahmen von komplexen Hochrisiko-Koronarinterventionen
Hamann, J., Schmidt, F., & Ibrahim, K. S. (2024) · Kardiologie up2date · doi:10.1055/a-1991-0220 · Cited by 1
Al-Buluk Children's Hospital in Khartoum
Eltahir, E. M., Abdelhafiz, K., Ali, M., Abdelgalil, S., & Thomas, E. S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00297-6 · Cited by 1
Inflammation, infection, and cardiovascular risk
Strandberg, T. E., Kovanen, P. T., & Gylling, H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02876-3 · Cited by 1
Schettler, V. J. J. (2022) · Dialyse aktuell · doi:10.1055/a-1857-8123
Cintezǎ, M. (2022) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2022.17.3.555
Alieva, A. S., Usova, E., & Reutova, O. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i2.14
[Advances in diagnosis and treatment of familial hypercholesterolemia].
Zheng, H., Jiang, S., & Li, L. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.01.22
The key role of trials in cardiovascular medicine: challenges and opportunities
Crea, F. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad110
Coronary stenting for stable coronary ischaemia: ain't misbehaving, just misunderstood
Chew, D. P., & Zaman, S. J. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52050
Therapeutic combination of "keys" to target low-density lipoprotein cholesterol level
Кашталап, В. В., & Sedykh, D. Y. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-110
Wang, H., Liu, Z., Yang, Z., Lu, Y., & Zou, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4537908/v1
Kontush, A. (2024) · Wiley eBooks · doi:10.1002/9781394158393.ch9b
Head and Neck Cancer and Lipid Levels: New Horizons in Pathophysiology and Treatments
Yiğin, A. K., Ağırbaşlı, D., & Ağırbaşlı, M. A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_351
Zeenny, R. M., Abdo, R., Haddad, C., Hajj, A., Zeidan, R. K., Salameh, P., & Ferrières, J. (2024) · Pharmacy · doi:10.3390/pharmacy12060171
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 1
Araújo, A. S., Vieira, G., de Santana, E. S., GARBELINI, V. B., Buzzetto, M., Rocha, E. M. L., Rothenburg, I. T., Carvalho, P. A., Lima, J. L. D. O., Souza, A. L., et al. (2025) · International Journal of Health Science · doi:10.22533/at.ed.159552515012
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100739
Yatskov, I. A., Dudchenko, L. S., Маисович, М. Ф., Beloglazov, V. A., Solovyova, E. A., & Николаевна, А. Г. (2025) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2025-10.1.23
Weekly Journal Scan: obicetrapib and the revival of cholesteryl ester transfer protein inhibition
Vergallo, R., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf467
Galatius, E. S., Lassen, M. C. H., Skaarup, K. G., Johansen, N. D., Galatius, S., Jensen, G. B., Schnohr, P., Møgelvang, R., & Biering‐Sørensen, T. (2025) · Echocardiography · doi:10.1111/echo.70249
Treatment of dyslipidemia: PCSK-9 in focus
Lukač, S. S., Popović, L., Rasulić, I., Petakov, A., Bogdanović, J. M., Mitrović, M., Krstic, M., & Lalic, K. S. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-55356
Sedykh, D. Y., & Кашталап, В. В. (2025) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2025-14-4-256-264
He, K., Ku, X., Chen, Z., Wu, C., Liao, C., Li, L., Qu, H., Hong, P., Bai, S., Cui, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678175
Vilela, E., & Bettencourt, N. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250386
Vilela, E., & Bettencourt, N. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250386i
Gabr, S. A. (2025) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20250675
Update in Cardiovascular Health
Faubion, S. S., Kapoor, E., & Kling, J. M. (2025) · Journal of Women s Health · doi:10.1177/15409996251392794
Dai, Y., Qiu, C., Zhang, D., Li, M., & Liu, W. (2024) · Figshare · doi:10.6084/m9.figshare.25067200
Dai, Y., Qiu, C., Zhang, D., Li, M., & Liu, W. (2024) · Figshare · doi:10.6084/m9.figshare.25067321
Dai, Y., Qiu, C., Zhang, D., Li, M., & Liu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26673021
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · medRxiv · doi:10.64898/2026.01.01.26343323
Sensing changes in triglyceride concentration in blood solution using diffuse optical spectroscopy
Liang, S., Wan, N., Chen, G., Chen, S.-L., & Seong, M. (2026) · Optics & Laser Technology · doi:10.1016/j.optlastec.2026.114767
Management and Therapy of Dyslipidemia
Marschang, P. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_23
Another brick in the wall of severe hypertriglyceridaemia lowering
Pedicino, D., & Vergallo, R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag124
Lagou, S., Barkas, F., Giannakopoulou, S., Koutsogianni, A.-D., Adamidis, P. S., Anastasiou, G., Kyrili, K., Chrysohoou, C. A., Tsioufis, C., Pitsavos, C., et al. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_4_25
Oliveira, J. R. C. D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014177
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05302-z
How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature
Zhang, J., Tong, J., Sun, Y., Sun, J., Gao, R., Sun, D., Guo, X., & Wei, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s563561
The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion
Panteloglou, G., Robert, J., Smit, M., Huijkman, N., Kloosterhuis, N., Law, C. S., Woods, B., Othman, A., Kleber, M. E., Delgado, G., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121887
Compound Lingzhi granules alleviated atherosclerosis by reducing lipid accumulation and inflammation
Hu, J., Liu, J., 常英新, Li, Z., Liu, S., Zheng, G., Fan, F., Miao, Y., Zhang, X., Shi, J., et al. (2026) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2026.06.007
Sarti, A., Sciaramenti, G., Camaiti, G., Cioci, P., Rizza, C., Tezze, R., Vocale, L. R., Hoxha, K., Maccaferri, I., Paparazzo, F., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166358
Current Challenges in the Early Prevention of Atherosclerotic Cardiovascular Disease
Kouvari, M., Giannakopoulou, S., Agouridis, A. P., Malikides, V., & Magriplis, E. (2026) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_32_26
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
Shishkova, D. K., Kanonykina, A., Андреевич, К. Е., Евгеньевна, Т. А., Lazebnaya, A. A., Klyueva, A. A., Agalaryan, S., & Кутихин, А. Г. (2026) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2026-15-1-189-202
Metadata
- Authors
- Tokgözoğlu, L., & Libby, P.
- Affiliations
- Hacettepe University (TR)
- Brigham and Women's Hospital (US)
- Corresponding author
- Libby, Peter
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-20
- Volume
- 43
- Issue
- 34
- Pages
- 3198-3208
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC9448630
- OpenAlex
- W4205823791
- Cited by
- 171
- References
- 116
- Citations by year
- 2026: 20 · 2025: 49 · 2024: 59 · 2023: 31 · 2022: 12
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (1R01HL134892)
- American Heart Association
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipid-lowering therapy, LDL cholesterol, cardiovascular risk, apolipoprotein C-III, ANGPTL3, ANGPTL4, ATP citrate lyase, triglyceride-rich lipoproteins, lipoprotein(a), PCSK9 inhibitors, genome editing, genetic risk factors, atherosclerosis
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Triglycerides, Lipoprotein(a), Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
